Amylyx Pharmaceuticals

NSQ:AMLX · US03237H1014

PharmaceuticalsSmall

360° View

Value46

Price/Sales12

Price/Earnings88

Price/Book10

Dividend Yield—

Growth24

Revenue Growth1

Profit Growth28

Capital Growth5

TSR 52w77

Safety72

Leverage60

Liquidity58

Refinancing55

Combined38

Sentiment89

Analyst Opinions89

Pro Holdings93

Opinion Changes50

Market Pulse1

Profile

CountryUSA

IndustryPharmaceuticals

SizeSmall

TypePublic Company

ExchangeNASDAQGS

Founded2014

Employees157

Websiteamylyx.com

ISINUS03237H1014

Last UpdateApr 2, 2026

Index & Theme

NeurologyCentral Nervous SystemNeuroscienceEndocrinologyBiotechnologyMedicalPharmaceutical

Description

Amylyx Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company. The company has preclinical and clinical development programs underway in endocrine conditions and neurodegenerative diseases. The company is advancing a pipeline in w…

Analysis

Amylyx Pharmaceuticals's 360° View rank of 67 places it above its peer average — better than 67% of its true peers.

It's lagging on growth (24) and on the expensive side (46). On safety it is financially sound (72), and the market shows strongly positive sentiment (89). Taken together, its Combined rank of 38 reads as below its peer average.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Amylyx Pharmaceuticals with its peers

MBX Biosciences

NSQ:MBX

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Zevra Therapeutics

NSQ:ZVRA

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Terns Pharmaceuticals

NSQ:TERN

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Cognition Therapeutics

NAQ:CGTX

—

CountryUSA

IndustryPharmaceuticals

SizeX-Small

Full Stock Analysis →

Oramed Pharmaceuticals

NAQ:ORMP

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Ironwood Pharmaceuticals

NSQ:IRWD

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →